X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The license agreement covers the combination of COYA 301 with GM-CSF and additional immune analogues and provides a next generation approach with a novel combination to synergistically modulate and reduce inflammation.
Lead Product(s): COYA 301,GM-CSF
Therapeutic Area: Immunology Product Name: COYA 301
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: UNeMed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 13, 2024
Details:
COYA 302 is a dual-mechanism investigational biologic combination immunotherapy comprised of proprietary low dose IL-2 and fusion protein CTLA-4 Ig. It is being evaluated for the treatment of frontotemporal dementia and parkinson’s disease.
Lead Product(s): COYA 302
Therapeutic Area: Neurology Product Name: COYA 302
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
COYA 302 is a dual-mechanism investigational biologic combination therapy comprised of proprietary low dose IL-2 and fusion protein CTLA-4 Ig. It is being evaluated for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Lead Product(s): COYA 302
Therapeutic Area: Neurology Product Name: COYA 302
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2024
Details:
The net proceeds will be used to support preclinical, clinical, and regulatory activities related to the company’s existing and future product candidate pipeline including COYA-201 which is under preclinical development for autoimmune, metabolic, neurodegenerative disorders.
Lead Product(s): COYA-201
Therapeutic Area: Immunology Product Name: COYA-201
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: BTIG, LLC
Deal Size: $26.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement December 12, 2023
Details:
Under the agreement, Coya granted Dr. Reddy’s an exclusive license to commercialize COYA 302, a proprietary co-pack kit containing combination of low dose interleukin-2 and CTLA-4 Ig (abatacept) for the treatment of Amyotrophic Lateral Sclerosis.
Lead Product(s): Interleukin 2,Abatacept
Therapeutic Area: Neurology Product Name: COYA 302
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Dr. Reddy\'s Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 06, 2023
Details:
COYA 301 is a treg-enhancing biologic therapy, which will be supplied in a pre-filled syringe for subcutaneous injection, which is investigated for the treatment of alzheimer’s disease.
Lead Product(s): Coya 301
Therapeutic Area: Neurology Product Name: Coya 301
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2023
Details:
COYA 302 is a combination of COYA 301 (low dose IL-2) and CTLA4-Ig fusion protein. It is intended to enhance Treg function in vivo and downregulate the function of T effector cells, proinflammatory cells and lipid peroxides for treating ameliorate disease progression.
Lead Product(s): Coya 302
Therapeutic Area: Neurology Product Name: Coya 302
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2023
Details:
Under the agreement, Coya will in-license the proposed Abatacept biosimilar for the development of Coya’s combination product for neurodegenerative diseases, COYA 302, an investigational combination biologic for subcutaneous administration, comprised of COYA 301 and CTLA4-Ig.
Lead Product(s): Coya 301,Abatacept
Therapeutic Area: Neurology Product Name: Coya 302
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Dr. Reddy\'s Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 20, 2023
Details:
Under the agreement with ARScience, Coya has been granted the rights to develop and commercialize COYA 301 as a monotherapy for the treatment of multiple autoimmune diseases. COYA 301 is an immunomodulatory cytokine, intended to enhance regulatory T cell (Treg) function.
Lead Product(s): Coya 301
Therapeutic Area: Neurology Product Name: Coya 301
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: ARScience Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 15, 2023
Details:
COYA 301 is a biologic for subcutaneous administration intended to enhance Treg function in vivo for the treatment of FTD, an orphan disease of high unmet need. It is being investigated for frontotemporal dementia.
Lead Product(s): Coya 301
Therapeutic Area: Neurology Product Name: Coya 301
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
